司美格鲁肽与2型糖尿病成人新生血管性年龄相关性黄斑变性
结果显示,与度拉糖肽、恩格列净、西格列汀、格列吡嗪等对照药物相比,司美格鲁肽使用者的NVAMD风险未见差异,未发现风险升高或降低的证据。
要点
- 司美格鲁肽使用者NVAMD风险与度拉糖肽、恩格列净、西格列汀、格列吡嗪使用者相比均无显著差异。
- 自身对照病例系列分析未发现司美格鲁肽暴露与NVAMD风险升高或降低相关(NVAMD-C:IRR 0.92;NVAMD-CP:IRR 1.02)。
- 研究采用条件码与条件码联合操作两种NVAMD定义,结论一致,均未提示风险改变。
核心结论
- 在2型糖尿病成人中,未检测到司美格鲁肽使用与新生血管性年龄相关性黄斑变性风险存在差异。
研究设计与样本
- 回顾性研究,覆盖观察性健康数据科学与信息学网络12个数据库,时间范围为2017年12月1日至2024年12月31日。
- 采用活性对照队列设计(倾向评分校正Cox比例风险模型估计HR)与自身对照病例系列分析(条件Poisson回归估计IRR),并以随机效应荟萃分析生成网络-wide估计。
主要发现
- 与度拉糖肽相比:NVAMD-C的HR为0.57(95%CI 0.21-1.57,P=0.28),NVAMD-CP的HR为0.25(95%CI 0.05-1.27,P=0.10)。
- 与恩格列净相比:NVAMD-C的HR为0.98(95%CI 0.54-1.79,P=0.94),NVAMD-CP的HR为0.79(95%CI 0.38-1.64,P=0.52)。
- 与西格列汀相比:NVAMD-C的HR为2.08(95%CI 0.90-4.83,P=0.09),NVAMD-CP的HR为1.80(95%CI 0.55-5.86,P=0.33)。
- 与格列吡嗪相比:NVAMD-C的HR为0.83(95%CI 0.35-2.02,P=0.69),NVAMD-CP的HR为0.50(95%CI 0.21-1.19,P=0.12)。
- 自身对照病例系列分析:NVAMD-C的IRR为0.92(95%CI 0.67-1.26,P=0.60),NVAMD-CP的IRR为1.02(95%CI 0.76-1.36,P=0.92);其他GLP-1受体激动剂或非GLP-1受体激动剂亦未发现关联。
关键数值与推荐
- NVAMD定义包括仅基于条件码的NVAMD-C和基于条件码联合操作的NVAMD-CP两种。
- 活性对照队列采用倾向评分校正Cox比例风险模型估计HR,自身对照病例系列采用条件Poisson回归估计IRR。
- 网络-wide估计通过随机效应荟萃分析生成HR和IRR。
临床怎么用
- 对于合并2型糖尿病且需要GLP-1受体激动剂治疗的患者,现有观察性证据未提示司美格鲁肽增加新生血管性年龄相关性黄斑变性风险。
- 临床决策时可结合患者眼底状况个体化评估,无需仅因NVAMD风险顾虑而停用司美格鲁肽。
局限性
- 原文未报告具体局限性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the potential association of semaglutide use and neovascular age-related macular degeneration (NVAMD). DESIGN: Retrospective study across 12 databases in the Observational Health Data Sciences and Informatics network from December 1, 2017, through December 31, 2024. PARTICIPANTS: Adults with type 2 diabetes (T2D) taking semaglutide, other glucagon-like peptide-1 receptor agonists (GLP-1RAs; e.g., dulaglutide or exenatide), or non-GLP-1RAs (e.g., empagliflozin, sitagliptin, or glipizide). METHODS: The association between semaglutide use and NVAMD was assessed using 2 approaches: an active-comparator cohort design and a self-controlled case series analysis. The former used propensity score-adjusted Cox proportional hazards models to estimate hazard ratios (HRs). The latter used conditional Poisson regression models to estimate incidence rate ratios (IRRs). A random-effects meta-analysis was used to generate network-wide HR and IRR estimates. MAIN OUTCOME MEASURES: Two definitions of NVAMD, one based on condition codes alone (NVAMD-C) and one based on condition codes and procedures (NVAMD-CP). RESULTS: A total of 227 971 new users of semaglutide were included in the study. The risk of NVAMD among semaglutide users was similar to that of users of dulaglutide (NVAMD-C: HR, 0.57; 95% CI, 0.21-1.57; P = 0.28; NVAMD-CP: HR, 0.25; 95% CI, 0.05-1.27; P = 0.10), empagliflozin (NVAMD-C: HR, 0.98; 95% CI, 0.54-1.79; P = 0.94; NVAMD-CP: HR, 0.79; 95% CI, 0.38-1.64; P = 0.52), sitagliptin (NVAMD-C: HR, 2.08; 95% CI, 0.90-4.83; P = 0.09; NVAMD-CP: HR, 1.80; 95% CI, 0.55-5.86; P = 0.33), and glipizide (NVAMD-C: HR, 0.83; 95% CI, 0.35-2.02; P = 0.69; NVAMD-CP: HR, 0.50; 95% CI, 0.21-1.19; P = 0.12). No evidence was found of increased or decreased risk for NVAMD associated with semaglutide exposure (NVAMD-C: IRR, 0.92; 95% CI, 0.67-1.26; P = 0.60; NVAMD-CP: IRR, 1.02; 95% CI, 0.76-1.36; P = 0.92) nor with any of the other GLP-1RAs or non-GLP-1RAs. CONCLUSIONS: We detected no differences in the risk of NVAMD associated with semaglutide use among adults with T2D. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Cai CX, Toy B, Martin B, et al. Semaglutide and Neovascular Age-Related Macular Degeneration among Adults with Type 2 Diabetes: An Observational Health Data Sciences and Informatics Network Study. Ophthalmology. 2026. PMID: 42229813. doi:10.1016/j.ophtha.2026.05.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。